Inhibrx Biosciences Stock Plunges 7% After Higher Borrowing Costs Widen Its Quarterly Loss
The cancer-treatment developer cut research spending, but its loan balance rose to $275 million from $100 million a year earlier.
Inhibrx Biosciences, which develops experimental biologic therapies, plunged 7.4% to $77.18 in Monday trading, as of 1:26 PM ET, erasing $90 million in market value. The decline followed Friday's results: a net loss of $38.7 million for the quarter, up from $35.3 million a year earlier, which the company attributed to higher borrowing costs.
A Bigger Loan Bill
Inhibrx's loan balance reached $275 million, compared with $100 million a year earlier. The company identified interest on that balance as the main reason other expenses climbed to $7 million from $1.4 million.
Research spending fell to $26 million from $28.5 million a year earlier. Management attributed the reduction mainly to cheaper trials and fewer employees.
Administrative spending rose as Inhibrx prepared for a potential launch of its chondrosarcoma treatment. The company ended September with $199.5 million in cash and equivalents.
Five Declines In A Row
The stock was on pace Monday for its fifth straight daily decline. Its market value stood at $1.1 billion in Monday trading.
Inhibrx shares were up 5% for the year at Friday's close, trailing the S&P 500's 11% gain. Even with that positive return, the shares ended Friday 41% below their highest close of the past year.
Cancer Programs Still In Trials
Inhibrx has no approved products. Its business centers on two cancer programs in clinical trials, using its own protein-engineering platforms to build biologic treatment candidates.
Ozekibart targets DR5, a receptor involved in cell death, and is being studied in chondrosarcoma, Ewing sarcoma, colorectal cancer and other solid tumors. INBRX-106 targets OX40, an immune-cell receptor, and is being tested alone and with Merck's Keytruda in non-small cell lung cancer and head and neck squamous cell carcinoma.
Inhibrx became a stand-alone public company through a May 2024 spin-off from its former parent. As of December 31, 2025, it solely owned 31 patent families.
Inhibrx expects initial results around mid-2027 from its expanded ordastobart head-and-neck cancer study, with FDA discussions and a planned late-stage confirmatory trial to follow.
Sources
- The company's filing (Inhibrx Biosciences) — SEC filing
- Inhibrx Biosciences — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR